Business Context and Reporting Period
Company: Inspire Medical Systems, Inc. (INSR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: Inspire is a medical technology company focused on the Inspire system, a neurostimulation therapy for moderate to severe obstructive sleep apnea (OSA). The company operates as a single segment, selling primarily to hospitals and ambulatory surgery centers in the U.S. (95.8% of H1 2025 revenue) and select international markets.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Amount (in thousands) | YoY Change |
|---|---|---|
| Revenue | $418,403 | +16.3% |
| Gross Profit | $353,022 | +15.6% |
| Gross Margin | 84.4% | -40 bps |
| Operating Loss | $(4,801) | Improved from $(10,119) |
| Net Loss | $(600) | Worsened from $(212) |
| Cash & Equivalents | $106,927 | -28.8% (vs. Dec 31, 2024) |
| Total Investments | $303,798 | -17.4% (vs. Dec 31, 2024) |
| Working Capital | $479,830 | -11.5% (vs. Dec 31, 2024) |
| Operating Cash Flow | $(4,019) | Shifted from $8,782 inflow |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased $58.5 million (16.3%) year-over-year, driven by a $57.2 million increase in U.S. sales and $1.3 million internationally. Growth was attributed to increased market penetration and awareness.
- Margin Compression: Gross margin decreased to 84.4% from 84.8% in the prior year period. This was primarily due to a $2.1 million charge for excess component parts related to the Inspire IV system, partially offset by volume benefits.
- Expense Trends:
- SG&A: Increased $46.1 million (17.9%) due to higher compensation (headcount growth), legal fees, and marketing costs.
- R&D: Decreased $3.7 million (6.4%) due to reduced development costs for next-generation products, partially offset by higher compensation.
- Non-Operating Items: Other income decreased $5.0 million, largely due to a $4.0 million impairment charge on a strategic investment and lower interest income.
- Share Repurchases: The company utilized its full $150 million share repurchase authorization, spending $75.0 million in the first half of 2025 (including an accelerated share repurchase settlement).
Outlook, Risks, and Management Commentary
- Product Transition (Inspire V): The Inspire V system was fully launched in the U.S. in May 2025. Management notes that some patients and physicians are delaying therapy until Inspire V is available at their centers, and customers are destocking Inspire IV inventory. This is expected to impact revenue through the second half of 2025.
- Competitive Landscape (GLP-1s): The rise of GLP-1 medications (e.g., Zepbound) for weight loss and OSA treatment is a noted risk. While management believes these drugs may eventually expand the eligible patient pool by reducing BMI, some prospective patients are currently delaying Inspire therapy to trial these medications.
- Legal Proceedings:
- A federal securities class action (City of Hollywood) was dismissed with prejudice in March 2025.
- A stockholder derivative lawsuit (Hollin) was voluntarily dismissed in September 2024.
- The company is cooperating with a Department of Justice investigation regarding marketing and reimbursement practices (CID issued Jan 2025).
- In May 2025, Inspire sued competitor Nyxoah SA for patent infringement regarding the Genio device.
- Liquidity: The company holds $410.7 million in cash, cash equivalents, and investments. Management believes this is sufficient to fund operations for at least the next 12 months.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) was enacted on July 4, 2025. The company is evaluating its impact on financial statements, with finalization expected by the end of Q3 2025.
Investor Verification Checklist
- Inventory Levels: Verify the $121.6 million inventory balance and the specific impact of the $2.1 million Inspire IV excess component charge on future margins.
- Revenue Timing: Assess the duration of the "destocking" effect and Inspire V adoption delays; confirm if Q3/Q4 revenue guidance accounts for this transition.
- Share Repurchase Status: Confirm that the $150 million repurchase program is fully exhausted as of June 30, 2025, and evaluate the impact on future capital allocation.
- Legal Exposure: Monitor the status of the DOJ investigation and the patent infringement lawsuit against Nyxoah for potential financial or operational impacts.
- GLP-1 Impact: Track clinical data and market trends regarding GLP-1 usage in OSA patients to gauge long-term demand elasticity for Inspire therapy.